Compare LSF & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSF | GRDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United Kingdom |
| Employees | 28 | 2 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 39.3M |
| IPO Year | 2020 | N/A |
| Metric | LSF | GRDX |
|---|---|---|
| Price | $4.55 | $4.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 78.2K | 76.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $49,889,286.00 | N/A |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.64 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $1.87 |
| 52 Week High | $7.80 | $6.93 |
| Indicator | LSF | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 44.88 |
| Support Level | $2.23 | $2.01 |
| Resistance Level | $5.11 | $5.30 |
| Average True Range (ATR) | 0.41 | 0.47 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 41.25 | 19.16 |
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.